Relistor

Relistor by Salix Pharmaceuticals treats opioid-induced constipation in patients with chronic non-cancer pain, enhancing bowel function without affecting pain relief. Available as tablets or injections, it works as a peripherally-acting mu-opioid receptor antagonist to target gastrointestinal sites.

Manufacturer

Salix Pharmaceuticals Inc

Formulation

oral / tablet

Active: methylnaltrexone bromide

Approved

7/19/2016

Expires

3/10/2031

Manageable Constraints

ACNU Feasibility

View full report

Relistor, an oral opioid antagonist, has moderate side effects and requires monitoring, especially for GI risks. Its injection dosing complexity and adherence challenges reflect usability concerns, but it has low misuse potential and minimal tolerance risk.